We herewith submit Audited Financial Results for the Quarter and year ended on March 31, 2025.

Revenue declinedNet loss reportedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹35.90

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-2.8% vs market

Commodity Chemicals peers, median of 52sector-0.1%-2.3% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.3 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5+0.3-2.8-0.1-2.3

Next day

-2.5+0.7-3.2-0.2-2.3

+2.6+1.0+1.6-0.1+2.7

-0.1+1.1-1.2-0.5+0.4

+1.6+0.8+0.8-0.5+2.1

+0.0+1.3-1.3-0.1+0.1

-2.5+1.7-4.3-0.4-2.1

15d

+0.3+1.5-1.2-0.1+0.4

+4.5+4.0+0.4+1.4+3.0

+1.3+1.8-0.5-1.7+2.9

-9.0-1.0-8.1-3.7-5.3

UpDownMarket · Nifty Microcap 250Sector · Commodity Chemicals peers, median of 52Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Link Pharma Chem Ltd reported a continued loss for FY25, though narrower than the previous year. Revenue from operations fell to Rs 2,543.34 lakhs from Rs 2,989.77 lakhs in FY24, a drop of about 15%. The company posted a net loss of Rs 102.73 lakhs in FY25 versus a loss of Rs 136.29 lakhs in FY24, with EPS of Rs (2.31) vs Rs (3.07). Q4 FY25 revenue dropped to Rs 644.66 lakhs from Rs 803.24 lakhs in Q4 FY24, swinging from a small profit to a loss of Rs 35.02 lakhs. The balance sheet shrank modestly, but total borrowings declined sharply from Rs 922 lakhs to Rs 578 lakhs, and operating cash flow turned positive at Rs 268.59 lakhs vs a near-zero figure last year. Auditor CNK & Associates issued an unmodified opinion.

Likely market impact

Continued top-line decline and losses are negative for shareholders, but the narrower loss, debt reduction, and positive operating cash flow suggest some operational improvement. The stock may remain under pressure given the persistent unprofitability.